Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEveSTA: Sequential vs Standard Bevacizumab-based Chemotherapy in First-line Metastatic Colorectal Cancer
2013-003244-23Phase 3Active
- Sponsor
- Southern Italy Cooperative Oncology Group
- Start
- Feb 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, irinotecan, oxaliplatin, capecitabine, fluorouracil and 1 more in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (3 arms), sponsored by Southern Italy Cooperative Oncology Group. Primary endpoint: Progression-free survival. Started Feb 2014; status: active.
02
Drugs
bevacizumabirinotecanoxaliplatincapecitabinefluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-003244-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003244-23.